Endosomal Reactive Oxygen Species In Tumour Angiogenesis
Funder
National Health and Medical Research Council
Funding Amount
$633,739.00
Summary
Cancer claims more lives worldwide than any other disease affecting millions of people annually. Tumours grow and spread in the body by acquiring their own blood vessels that provide them with nutrients and oxygen. We have identified a new protein called NADPH oxidase that promotes the development of these new blood vessels in tumours. We propose to test new drugs that block NADPH oxidase activity to stop the development of new blood vessels for the potential treatment of cancer
Mitochondrial Complex II Is A New Target For Anti-cancer Drugs
Funder
National Health and Medical Research Council
Funding Amount
$448,434.00
Summary
Cancer is a huge problem and is most likely to get worse. Therefore, new approaches to treatment are necessary. Cancer cells constantly mutate, so many established drugs cannot be used. A very promising approach is targeting mitochondria, the powerhouse of the cells. This is because these organelles are important for all cancer cells. We are proposing a novel way of using mitochondria as targets for a group of anti-cancer drugs that would ultimately result in efficient cancer management.
There are ~1.6 billion overweight adults worldwide & this is predicted to rise to 2.3 billion by 2015. In Australia > 2/3 of adults are overweight or obese. Obesity is a key factor in the progression of many human malignancies. Obesity poses the greatest risk for the development hepatocellular carcinoma (HCC), a deadly cancer refractory to nearly all available anti-cancer therapies. This application will delineate the molecular mechanisms by which obesity promotes HCC development.
The Role Of Redox Regulation In Controlling The Oncogenic Function Of Eph Receptors
Funder
National Health and Medical Research Council
Funding Amount
$71,766.00
Summary
Reactive oxygen species (ROS) produced in cancers activate cell surface receptor signalling pathways that drive cancer progression. I will study links between ROS and receptor signalling in cancer cells, and inhibit signalling with ROS scavengers delivered in nanoparticles, targeted to receptor complexes with specific antibodies. These will include antibodies we raised against ADAM10, a protease associated with multiple receptor signalling pathways, to simultaneously inhibit these pathways.